Review
Medicine, General & Internal
Claire Gorry, Laura McCullagh, Helen O'Donnell, Sarah Barrett, Susanne Schmitz, Michael Barry, Kay Curtin, Eamon Beausang, Rupert Barry, Imelda Coyne
Summary: This review evaluated the effects of neoadjuvant treatment on stage III and IV cutaneous melanoma. The findings suggest that there is insufficient evidence to support the use of neoadjuvant treatment in clinical practice.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2023)
Article
Oncology
Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Celeste Lebbe, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stephane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Michele Maio
Summary: The study aimed to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in patients with advanced melanoma. It found that the treatment was tolerable and had similar efficacy in all treated population with various subgroups, but reduced efficacy in patients with specific characteristics, indicating a need for novel treatment options.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
ChuanLiang Cui, Xuan Wang, Bin Lian, Qing Ji, Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert Andtbacka, Jun Guo
Summary: The modified oncolytic virus OrienX010 was evaluated in Chinese patients with melanoma, and the results showed that it had antitumor effects in both injected and non-injected lesions with tolerable safety profile. The higher dose was selected as the recommended dose for ongoing trials based on these findings.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel Clarke-Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca Baergen
Summary: This study compared the efficacy and toxicity of cisplatin plus paclitaxel with carboplatin plus paclitaxel in patients with resected advanced ovarian cancer. The results showed that the carboplatin plus paclitaxel regimen had less toxicity, was easier to administer, and was not inferior to the cisplatin plus paclitaxel regimen.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Daan Reesink, Harm H. E. van Melick, Paul van der Nat, Maartje Los, Simon Horenblas, Ewoudt M. W. van de Garde, Santeon MIBC Study Grp
Summary: The study aimed to evaluate the efficacy-effectiveness gap in palliative first-line chemotherapy for urothelial carcinoma of the bladder. The findings show that the median overall survival of patients receiving gemcitabine + cisplatin (GemCis) was shorter compared to clinical trial results, indicating a gap between efficacy and real-world effectiveness. Patients treated with gemcitabine + carboplatin (GemCarbo) had worse prognostic characteristics, but had similar outcomes in terms of dose reductions, early termination, clinical best response, and toxicity compared to GemCis patients. The study suggests that GemCis treatment may not be superior to GemCarbo treatment.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Oncology
Daoan Cheng, Jing Hu, Xiaoyu Wu, Banglu Wang, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji
Summary: In patients with unresectable stage III/IV pancreatic cancer, PD-1 blockade combined with nab-paclitaxel and gemcitabine demonstrated superior efficacy compared to chemotherapy alone.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Yang Liu, Huan-Wei Liang, Xin-Bin Pan
Summary: This study aims to compare survivals between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients receiving first-line EGFR-TKI. The results showed that stage III patients had a better median progression-free survival (PFS) and similar median overall survival (OS) compared to stage IV patients. After propensity score matching (PSM) analysis, stage III patients showed a better median PFS and similar median OS compared to stage IV patients.
Article
Oncology
David E. Kozono, Thomas E. Stinchcombe, Joseph K. Salama, Jeffrey Bogart, W. Jeffrey Petty, Michael J. Guarino, Lyudmila Bazhenova, James M. Larner, Jared Weiss, Thomas A. DiPetrillo, Steven J. Feigenberg, Xin Chen, Zhaowen Sun, Silpa Nuthalapati, Lindsey Rosenwinkel, Eric F. Johnson, Bruce A. Bach, Yan Luo, Everett E. Vokes
Summary: This study evaluated the effects of veliparib in combination with chemoradiotherapy on patients with unresectable stage III NSCLC, demonstrating acceptable safety profile and antitumor activity with a median progression-free survival of 19.6 months.
Article
Oncology
Mario Mandala, James Larkin, Paolo Antonio Ascierto, Michele Del Vecchio, Helen Gogas, C. Lance Cowey, Ana Arance, Stephane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez, Marcus O. Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De la Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey Weber
Summary: Most treatment-related adverse events in adjuvant melanoma patients receiving nivolumab occurred early and resolved within 6 months, with no clear association between the occurrence of adverse events and recurrence-free survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
G. E. Konecny, A. E. Wahner Hendrickson, T. M. Davidson, B. J. Winterhoff, S. Ma, S. Mahner, J. Sehouli, P. A. Fasching, G. Feisel-Schwickardi, M. Poelcher, L. D. Roman, A. Rody, B. Y. Karlan, S. A. Mullany, H. Chen, I. L. Ray-Coquard, D. M. Provencher, A. Yachnin, P. H. Cottu, J. A. Glaspy, P. Haluska, D. J. Slamon
Summary: This study investigated the efficacy and safety of adding ganitumab to CP chemotherapy in primary EOC patients, but did not show improvement in PFS. The results do not support further study of ganitumab in unselected EOC patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Hisashi Tanaka, Yukihiro Hasegawa, Tomonori Makiguchi, Fumihiko Okumura, Chiori Tabe, Toshihiro Shiratori, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Junichi Yokouchi, Yoshiomi Hatayama, Masahiko Aoki, Sadatomo Tasaka
Summary: The study demonstrates that biweekly carboplatin and nab-paclitaxel with concurrent radiotherapy for patients with LA-NSCLC show good tolerability and promising antitumor activity, especially in terms of 2-year overall survival rate and objective response rate.
CLINICAL LUNG CANCER
(2021)
Article
Oncology
Jorge D. Oldan, Benjamin C. Giglio, Eric Smith, Weiling Zhao, Deeanna M. Bouchard, Marija Ivanovic, Yueh Z. Lee, Frances A. Collichio, Michael O. Meyers, Diana E. Wallack, Amber Abernethy-Leinwand, Patricia K. Long, Dimitri G. Trembath, Paul B. Googe, Madeline H. Kowalski, Anastasia Ivanova, Jennifer A. Ezzell, Nana Nikolaishvili-Feinberg, Nancy E. Thomas, Terence Z. Wong, David W. Ollila, Zibo Li, Stergios J. Moschos
Summary: Clinical trials of combined IDO/PD1 blockade in metastatic melanoma failed to show additional clinical benefit compared to PD1-alone inhibition. We found that high melanoma cell-specific LAT1 and low IDO1 expression were associated with worse overall survival in MM. High melanoma tryptophan metabolism is a poor predictor of pembrolizumab response and an adverse prognostic factor.
Article
Multidisciplinary Sciences
Wei Li, Li Wan
Summary: The cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC in the Chinese healthcare system was assessed. The results showed that sugemalimab consolidation therapy was not cost-effective without considering patient assistance program, but became a cost-effective option with the program.
Article
Immunology
Matias Tellado, Mariangela De Robertis, Daniela Montagna, Daniela Giovannini, Sergio Salgado, Sebastian Michinski, Emanuela Signori, Felipe Maglietti
Summary: This retrospective cohort study evaluated the addition of canine IL-2 gene electrotransfer (GET) peritumorally and IL-12 intramuscularly in inoperable canine oral malignant melanoma. The results showed that ECT+GET using IL-2 and IL-12 significantly improved progression-free survival in advanced stages of canine oral malignant melanoma.
Article
Oncology
Kathleen N. Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Maenpaa, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A. Gold, Yolanda Garcia, Sudarshan K. Sharma, Christopher J. Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana Molinero, Vidya Maiya, Victor K. Khor, Yvonne G. Lin, Sandro Pignata
Summary: The study evaluated the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody atezolizumab to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer, showing a significant progression-free survival advantage in the PD-L1-positive population. However, no significant overall survival benefit was observed from atezolizumab in the interim analysis. The most common grade 3 or 4 adverse events were neutropenia, hypertension, and anemia.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sami Antoun, Emilie Lanoy, Samy Ammari, Siham Farhane, Lisa Martin, Caroline Robert, David Planchard, Emilie Routier, Anne Laure Voisin, Sabine Messayke, Stephane Champiat, Jean Marie Michot, Salim Laghouati, Olivier Lambotte, Aurelien Marabelle, Vickie Baracos
Summary: The association between high body mass index (BMI) and longer survival in patients on immune checkpoint inhibitors (ICIs) is inconsistent. This study found that the 'obesity paradox' disappeared when accounting for confounders such as cancer type and manifestations of depletion. Weight loss and reduced skeletal muscle mass were observed in patients across all BMI categories, and weight loss was associated with shorter survival in both melanoma and non-small cell lung cancer (NSCLC) patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Stefanie Meyer, Lorenz Buser, Sebastian Haferkamp, Mark Berneburg, Tim Maisch, Monika Klinkhammer-Schalke, Armin Pauer, Thomas Vogt, Claus Garbe
Summary: By studying 439 patients with early-stage cutaneous melanoma, a new 7-biomarker signature was found to independently predict disease-free survival, melanoma-specific survival, and overall survival, regardless of AJCC classification. This 7-biomarker signature provides valuable complementary information to clinicopathological and demographic factors, improving the accuracy of prognosis for melanoma patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ulrike Keim, Alexander Katalinic, Bernd Holleczek, Marlies Wakkee, Claus Garbe, Ulrike Leiter
Summary: In this study, the aim was to analyze the incidence rates of cSCC over three decades and make predictions for 2040. The research findings showed that the incidence rates of cSCC were increasing in all investigated countries, particularly among individuals aged over 60. The extrapolation results indicated that the incidence rates of cSCC would continue to rise in all countries until 2044.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Rym Sfaxi, Biswendu Biswas, Galina Boldina, Mandy Cadix, Nicolas Servant, Huimin Chen, Daniel R. Larson, Martin Dutertre, Caroline Robert, Stephan Vagner
Summary: The recognition of polyadenylation signals (PAS) in eukaryotic pre-mRNAs is usually coupled to transcription termination, occurring while pre-mRNA is chromatin-bound. However, for some pre-mRNAs, this 3'-end processing occurs post-transcriptionally, i.e., through a co-transcriptional cleavage (CoTC) event downstream of the PAS, leading to chromatin release and subsequent PAS cleavage in the nucleoplasm. These findings indicate that CoTC-type cleavage of pre-mRNAs, followed by PAS cleavage in the nucleoplasm, allows certain pre-mRNAs to escape 3'-end processing inhibition in response to UV-induced DNA damage.
Letter
Oncology
Marie Boileau, Emilie Routier, Arnaud Pouvelle, Olivier Lambotte, Caroline Robert
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Celine Boutros, Djaouida Belkadi-Sadou, Antoine Marchand, Severine Roy, Emilie Routier, Caroline Robert
Summary: Immune checkpoint inhibitors (ICIs) have shown robust antitumor activity and tolerable safety in advanced melanoma. Long-term outcomes of patients who benefitted from this therapy and remain progression-free despite ICI discontinuation are now available. This review discusses the characteristics of long-term responders to ICIs and addresses the question of cure.
CURRENT ONCOLOGY REPORTS
(2023)
Article
Multidisciplinary Sciences
Andrey A. Yurchenko, Fatemeh Rajabi, Tirzah Braz-Petta, Hiva Fassihi, Alan Lehmann, Chikako Nishigori, Jinxin Wang, Ismael Padioleau, Konstantin Gunbin, Leonardo Panunzi, Fanny Morice-Picard, Pierre Laplante, Caroline Robert, Patricia L. Kannouche, Carlos F. M. Menck, Alain Sarasin, Sergey I. Nikolaev
Summary: Xeroderma pigmentosum (XP) is a rare genetic disorder associated with an increased risk of skin cancer. In this study, the authors analyze skin cancer genomes from five different XP groups, revealing genetic and molecular factors related to the mutational profile and UV-induced mutagenesis in XP.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbe, Harshada Joshi, Wendy Snyder, Janice M. Mehnert
Summary: In a randomized phase II study, the combination of T-VEC and ipilimumab showed greater antitumor activity compared to ipilimumab alone in patients with advanced melanoma. The 5-year outcomes demonstrated long-lasting efficacy and safety for the combination therapy of an oncolytic virus and a checkpoint inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Dirk Schadendorf, Hussein Tawbi, Evan J. Lipson, F. Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen, Melissa Hamilton, Shien Guo, Ling Shi, Sarah Keidel, Georgina Long
Summary: The RELATIVITY-047 trial demonstrates that the fixed-dose combination of nivolumab plus relatlimab improves progression-free survival in patients with advanced melanoma while maintaining stable health-related quality of life. Although the combination treatment is associated with a higher incidence of severe adverse events, patients' discomfort with these events is low, supporting NIVO + RELA as a first-line treatment option.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, Ralf Gutzmer
Summary: The outcome of advanced melanoma patients has greatly improved over the past 15 years. Targeted therapies blocking BRAF or inhibiting immune checkpoints have shown significant efficacy in improving overall survival. The COMBI-r study confirms the efficacy of dabrafenib plus trametinib in routine clinical practice and provides additional data in patients with brain metastases or previous treatments.
Article
Oncology
Esmee P. Hoefsmit, Franziska Vollmy, Elisa A. Rozeman, Irene L. M. Reijers, Judith M. Versluis, Liesbeth Hoekman, Alexander C. J. van Akkooi, Georgina Long, Dirk Schadendorf, Reinhard Dummer, Maarten Altelaar, Christian U. Blank
Summary: Taking into account the higher response rates of neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma compared to stage IV disease, researchers hypothesized that systemic immune suppression may be responsible for lower response rates and disease recurrence. Through proteomic profiling, they found that the protein LRG1 is associated with worse prognosis and can serve as a biomarker for identifying high-risk patients and as a potential target for neoadjuvant ICB therapy.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Paolo A. Ascierto, Reinhard Dummer, Helen J. Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion-Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T. Flaherty
Summary: The purpose of this study was to evaluate the efficacy and safety of encorafenib alone or in combination with binimetinib for the treatment of advanced BRAF(V600)-mutant melanoma. The results showed that the combination of encorafenib and binimetinib improved progression-free survival and overall response rate, and had better tolerability compared to encorafenib alone.
JOURNAL OF CLINICAL ONCOLOGY
(2023)